AMES, Iowa, April 15 /PRNewswire/ -- NewLink Genetics Corporation announced today that new data on its HyperAcute(R) lung cancer immunotherapy will be presented at a poster session at the 101st American Association for Cancer Research (AACR) Annual Meeting held April 17-21, 2010 in Washington, D.C.
NewLink’s HyperAcute cancer immunotherapies represent a unique approach to cancer therapeutics based on stimulating the same types of immune response that occur during hyperacute rejection of xenotransplants. The company’s products are composed of irradiated, allogeneic, whole cancer cells that have been genetically modified to add alpha(1,3)-Galactosyl (alphaGal) residues to cell-surface lipids and proteins. The alphaGal epitopes function as a molecular adjuvant, effectively harnessing the xenotransplant rejection mechanism.
About NewLink Genetics Corporation
NewLink Genetics Corporation is a biopharmaceutical company applying innovative technologies to create new therapeutic agents for patients with cancer and infectious diseases. Its products are designed to enhance the patient’s immune system, enabling the body’s immune cells to target pathogens and diseased tissues.
NewLink Genetics Corporation
